These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11796348)

  • 1. Selection of zone size interpretive criteria for disk diffusion susceptibility tests of three antibiotics against Streptococcus pneumoniae, using the New Guidelines of the National Committee for Clinical Laboratory Standards.
    Fuchs PC; Barry AL; Brown SD
    Antimicrob Agents Chemother; 2002 Feb; 46(2):398-401. PubMed ID: 11796348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies.
    Davies TA; Kelly LM; Jacobs MR; Appelbaum PC
    J Clin Microbiol; 2000 Apr; 38(4):1444-8. PubMed ID: 10747123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae.
    Jorgensen JH; Swenson JM; Tenover FC; Barry A; Ferraro MJ; Murray PR; Reller LB
    J Clin Microbiol; 1996 Nov; 34(11):2679-84. PubMed ID: 8897164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting susceptibility of Streptococcus pneumoniae to ceftriaxone and cefotaxime by cefuroxime and ceftizoxime disk diffusion testing.
    Williams-Bouyer N; Hernandez A; Reisner BS
    J Clin Microbiol; 1999 Nov; 37(11):3707-10. PubMed ID: 10523580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of telithromycin against Streptococcus pneumoniae resistant to other antibiotics, including cefotaxime.
    Fuchs PC; Barry AL; Brown SD
    J Antimicrob Chemother; 2002 Feb; 49(2):399-401. PubMed ID: 11815588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of interpretive criteria and quality control limits for broth microdilution and disk diffusion antimicrobial susceptibility testing of Streptococcus pneumoniae.
    Jorgensen JH; Swenson JM; Tenover FC; Ferraro MJ; Hindler JA; Murray PR
    J Clin Microbiol; 1994 Oct; 32(10):2448-59. PubMed ID: 7814481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpretative criteria and quality control parameters for telithromycin disc diffusion susceptibility tests.
    Barry AL; Fuchs PC; Brown SD
    J Antimicrob Chemother; 2001 Jul; 48(1):121-5. PubMed ID: 11418522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms.
    Morosini MI; Cantón R; Loza E; Negri MC; Galán JC; Almaraz F; Baquero F
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2427-31. PubMed ID: 11502509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
    Mazzariol A; Koncan R; Vitali LA; Cornaglia G
    J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Dade MicroScan MICroSTREP antimicrobial susceptibility testing panel with selected Streptococcus pneumoniae challenge strains and recent clinical isolates.
    Jorgensen JH; McElmeel ML; Crawford SA
    J Clin Microbiol; 1998 Mar; 36(3):788-91. PubMed ID: 9508313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of cethromycin (ABT-773), a new ketolide, against Streptococcus pneumoniae strains that are not susceptible to penicillin or macrolides.
    Mason EO; Lamberth LB; Wald ER; Bradley JS; Barson WJ; Kaplan SL
    Antimicrob Agents Chemother; 2003 Jan; 47(1):166-9. PubMed ID: 12499186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors.
    Bemer-Melchior P; Juvin ME; Tassin S; Bryskier A; Schito GC; Drugeon HB
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2999-3002. PubMed ID: 11036012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of ketolides telithromycin and HMR 3004 against italian isolates of Streptococcus pyogenes and Streptococcus pneumoniae with different erythromycin susceptibility.
    Giovanetti E; Montanari MP; Marchetti F; Varaldo PE
    J Antimicrob Chemother; 2000 Dec; 46(6):905-8. PubMed ID: 11102408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibilities of 228 penicillin- and erythromycin-susceptible and -resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents.
    Ednie LM; Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1997 May; 41(5):1033-6. PubMed ID: 9145864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of ABT-773, telithromycin and eight other antimicrobials against erythromycin-resistant Streptococcus pneumoniae respiratory isolates of children.
    Johnson CN; Benjamin WH; Gray BM; Crain MC; Edwards KM; Waites KB
    Int J Antimicrob Agents; 2001 Dec; 18(6):531-5. PubMed ID: 11738340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.
    Jones RN; Jenkins SG; Hoban DJ; Pfaller MA; Ramphal R
    Diagn Microbiol Infect Dis; 2000 Jun; 37(2):93-8. PubMed ID: 10863103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro and bactericidal activities of telithromycin against penicillin-nonsusceptible, levofloxacin-resistant, and macrolide-resistant Streptococcus pneumoniae by time-kill methodology.
    Kays MB; Lisek CR; Denys GA
    Int J Antimicrob Agents; 2007 Mar; 29(3):289-94. PubMed ID: 17240118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae.
    Jorgensen JH; Crawford SA; McElmeel ML; Whitney CG
    Antimicrob Agents Chemother; 2004 Feb; 48(2):605-7. PubMed ID: 14742216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro killing of penicillin-susceptible, -intermediate, and -resistant strains of Streptococcus pneumoniae by cefotaxime, ceftriaxone, and ceftizoxime: a comparison of bactericidal and inhibitory activity with achievable CSF levels.
    Stratton CW; Aldridge KE; Gelfand MS
    Diagn Microbiol Infect Dis; 1995; 22(1-2):35-42. PubMed ID: 7587048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents.
    Pankuch GA; Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1998 Mar; 42(3):624-30. PubMed ID: 9517943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.